AMARIN CORP PLC\UK Operating Lease, Lease Income
AMARIN CORP PLC\UK (AMRN) reported Operating Lease, Lease Income of $249.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseLeaseIncome · last filed 2026-07-29
- AMARIN CORP PLC\UK operating lease, lease income for the quarter ending 2026-06-30 was $249.00K, a 0.00% change year-over-year.
- AMARIN CORP PLC\UK operating lease, lease income for the quarter ending 2026-03-31 was $249.00K, a 0.00% change year-over-year.
- AMARIN CORP PLC\UK operating lease, lease income for the quarter ending 2025-12-31 was $249.00K, a 0.00% change year-over-year.
- AMARIN CORP PLC\UK operating lease, lease income for the quarter ending 2025-09-30 was $249.00K, a 0.00% change year-over-year.
- AMARIN CORP PLC\UK operating lease, lease income for fiscal 2025 was $995.00K, a 0.00% change from fiscal 2024.
- AMARIN CORP PLC\UK operating lease, lease income for fiscal 2024 was $995.00K, a 9.10% increase from fiscal 2023.
- AMARIN CORP PLC\UK operating lease, lease income for fiscal 2023 was $912.00K.
| Period end | Operating Lease, Lease Income 3 month | Operating Lease, Lease Income 6 month | Operating Lease, Lease Income 9 month | Operating Lease, Lease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $249.00K 10-Q · filed 2026-07-29 | $497.00K 10-Q · filed 2026-07-29 | $747.00K derived: sum of 3 quarters · filed 2026-07-29 | $996.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $249.00K 10-Q · filed 2026-04-29 | $498.00K derived: sum of 2 quarters · filed 2026-04-29 | $747.00K derived: sum of 3 quarters · filed 2026-04-29 | $996.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $498.00K derived: sum of 2 quarters · filed 2026-03-02 | $747.00K derived: sum of 3 quarters · filed 2026-07-29 | $995.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $249.00K 10-Q · filed 2025-10-29 | $498.00K derived: sum of 2 quarters · filed 2026-07-29 | $746.00K 10-Q · filed 2025-10-29 | $996.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $249.00K 10-Q · filed 2026-07-29 | $497.00K 10-Q · filed 2026-07-29 | $747.00K derived: sum of 3 quarters · filed 2026-07-29 | $996.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $249.00K 10-Q · filed 2026-04-29 | $498.00K derived: sum of 2 quarters · filed 2026-04-29 | $747.00K derived: sum of 3 quarters · filed 2026-04-29 | $996.00K derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $498.00K derived: sum of 2 quarters · filed 2026-03-02 | $747.00K derived: sum of 3 quarters · filed 2026-03-02 | $995.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $249.00K 10-Q · filed 2025-10-29 | $498.00K derived: sum of 2 quarters · filed 2025-10-29 | $746.00K 10-Q · filed 2025-10-29 | $996.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $249.00K 10-Q · filed 2025-07-30 | $497.00K 10-Q · filed 2025-07-30 | $747.00K derived: sum of 3 quarters · filed 2026-03-02 | $996.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $249.00K 10-Q · filed 2025-05-07 | $498.00K derived: sum of 2 quarters · filed 2026-03-02 | $747.00K derived: sum of 3 quarters · filed 2026-03-02 | $996.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $498.00K derived: sum of 2 quarters · filed 2026-03-02 | $747.00K derived: sum of 3 quarters · filed 2026-03-02 | $912.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $249.00K 10-Q · filed 2024-10-30 | $498.00K derived: sum of 2 quarters · filed 2024-10-30 | $663.00K 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $249.00K 10-Q · filed 2024-07-31 | $414.00K 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $166.00K 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |